The Note That Prices Nothing Prices Everything Later
A SAFE feels free because no number changes hands at the moment of signing. No share count moves, no ownership percentage appears on a cap table, no board seat is named. This is precisely the design intent and precisely the danger. The instrument converts deferral of price into the appearance of deferral of consequence, and founders routinely confuse the two. The valuation cap is not a ceiling on what you raise; it is a floor on what you give away. When a founder accepts a $6M post-money cap to take $1.5M, they have already sold 25% of the company at a price the market has not yet validated — they simply will not feel the cut until the priced round forces conversion, by which point the dilution is contractual, not negotiable.
The mechanical trap lives in the word post-money. The 2018 redesign of the standard SAFE moved the cap to a post-money basis, which sounds like a clarification and is in fact a transfer of risk from investor to founder. Under a post-money cap, the SAFE holder is guaranteed their stated percentage after the SAFE money is counted but before the next equity round and its option-pool top-up. Every subsequent SAFE you stack does not dilute the earlier holders proportionally with you — it dilutes you alone. Founders who raise on three or four sequential post-money SAFEs because each one is "easy" frequently discover at the Series A that they have collectively sold 35% to 45% of the company before a lead investor has set a single term.
Compute the Fully-Diluted Number Before You Sign, Not After
The only honest way to read a SAFE is to convert it on paper the day it is offered, under the assumptions that will actually govern conversion. That means: cap divided by post-money cap gives the investor's floor percentage; the priced round adds its own dilution on top of yours; and the option pool refresh demanded by the incoming lead is carved almost entirely out of the founders' and prior holders' shares, not the new investors'. A worked sequence makes the gap visible.
- $1.5M on a $6M post-money cap = 25.0% sold, before anything else happens.
- A later $750K SAFE on a $9M cap adds 8.3%, but because it is post-money it does not share the first holder's dilution — it lands on you.
- The Series A lead takes 20% and requires a 10% post-money option pool refreshed pre-money — both of which fall disproportionately on common.
- Founders who modeled "we sold a third" routinely close the round holding closer to half of what they expected.
The discrepancy is not fraud and rarely even hard negotiation. It is the predictable arithmetic of an instrument optimized to be signed quickly and understood slowly. The discipline the Financial Lens demands is unglamorous: build the pro-forma cap table at the moment of the offer, not at the moment of conversion, and price every "free" dollar at its fully-diluted cost in basis points of ownership.
The Rights You Trade Are Worth More Than the Points
Dilution is the visible cost; control is the cost that compounds. The side letters that accompany SAFEs — and the conversion terms baked into them — frequently grant pro-rata rights, information rights, most-favored-nation clauses, and occasionally board observer seats to holders who have not yet bought a single share of stock. An MFN clause is the most underestimated of these: it silently rewrites every prior SAFE to the most generous terms you grant to any later one, meaning a single concession to a single investor cascades backward across your entire convertible stack. Founders negotiate each note in isolation and inherit the union of every term they ever offered.
The governance failure mode arrives at the priced round. Pro-rata rights held by a crowd of small SAFE investors can consume the allocation a serious Series A lead wants for itself, and a lead that cannot get its target ownership simply walks. Information rights granted casually become a standing obligation to a holder you may later wish to exit. The decision implication is therefore narrow and firm: treat every non-economic right in a SAFE as a permanent encumbrance on the company's future financing capacity, price it as such, and refuse to grant board-level or MFN terms in exchange for the small, early checks that least deserve them. The cheapest capital is rarely the cheapest to have taken.